Dr Aleksandra Braun, MD | |
315 S Manning Blvd, Albany, NY 12208-1707 | |
(518) 525-1550 | |
Not Available |
Full Name | Dr Aleksandra Braun |
---|---|
Gender | Female |
Speciality | Hospitalist |
Experience | 6 Years |
Location | 315 S Manning Blvd, Albany, New York |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598257032 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 313471 (New York) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Samaritan Hospital | Troy, NY | Hospital |
St Peter's Hospital | Albany, NY | Hospital |
Rome Memorial Hospital, Inc | Rome, NY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Samaritan Hospital Of Troy, New York | 6507770070 | 180 |
St Josephs Medical Pc | 4688855844 | 291 |
St Peters Hospital Of The City Of Albany | 2668460072 | 183 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Entity Name | Samaritan Hospital Of Troy, New York |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1043267727 PECOS PAC ID: 6507770070 Enrollment ID: O20031118000782 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Entity Name | Cogent Medical Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912941238 PECOS PAC ID: 7315836780 Enrollment ID: O20040312001215 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Entity Name | St Peters Hospital Of The City Of Albany |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518042357 PECOS PAC ID: 2668460072 Enrollment ID: O20040504001301 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Entity Name | St Josephs Medical Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1942501747 PECOS PAC ID: 4688855844 Enrollment ID: O20110221000744 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Aleksandra Braun, MD Po Box 14890, Albany, NY 12212-4890 Ph: () - | Dr Aleksandra Braun, MD 315 S Manning Blvd, Albany, NY 12208-1707 Ph: (518) 525-1550 |
News Archive
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus circulating in air conditioning systems.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.
› Verified 5 days ago
Munir Ahmed Khan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-1550 | |
Shannon Leigh Murawski, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Dept. Of Internal Medicine, Albany, NY 12208 Phone: 518-262-5377 | |
Joshua David Zamer, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-8600 Fax: 518-525-6891 | |
Dr. Tanya Nicole Corry, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave, Albany, NY 12208 Phone: 518-262-6279 Fax: 518-262-5718 | |
Luiz C Coelho, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7 Southwoods Blvd, 3rd Fl Capital Cardiology Associates Pc, Albany, NY 12211 Phone: 518-292-6000 Fax: 518-641-6766 | |
Dr. Rakhee Lal Ippili, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-1500 | |
Dr. Mikram Jafri, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 40 Andriana Ln, Albany, NY 12204 Phone: 347-771-6423 |